Systemic Lupus Erythematosus - Pipeline Review, H1 2020

May 2020 | 717 pages | ID: SA551E81228EN
Global Markets Direct

Abstracts

Systemic Lupus Erythematosus - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H1 2020, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

'Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.'

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 35, 22, 1, 72, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 1, 12 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
• The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Systemic Lupus Erythematosus - Overview
Systemic Lupus Erythematosus - Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics Assessment
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
Systemic Lupus Erythematosus - Drug Profiles
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Systemic Lupus Erythematosus, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2020
Systemic Lupus Erythematosus - Pipeline by ACEA Therapeutics Inc, H1 2020
Systemic Lupus Erythematosus - Pipeline by Akeso Inc, H1 2020
Systemic Lupus Erythematosus - Dormant Projects, H1 2020
Systemic Lupus Erythematosus - Discontinued Products, H1 2020
Systemic Lupus Erythematosus - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Systemic Lupus Erythematosus, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc
ACEA Therapeutics Inc
Akeso Inc
Alpine Immune Sciences Inc
Aluda Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
Apimeds Inc
APT Therapeutics Inc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
AstraZeneca Plc
Atlantic Bio Sci LLC
Aurinia Pharmaceuticals Inc
BellBrook Labs LLC
Bio-Path Holdings Inc
BioAegis Therapeutics Inc
Biocon Ltd
Biogen Inc
Biotest AG
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Carna Biosciences Inc
Cells for Cells SA
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
Citryll BV
Corbus Pharmaceuticals Inc
Corestem Inc
CuraVac Inc
Cyteir Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Domainex Ltd
Eli Lilly and Co
Epsilon-3 Bio Ltd
Ergon Pharmaceuticals LLC
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Galapagos NV
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
Genesen Co Ltd
Genosco Inc
Genovax Srl
Gilead Sciences Inc
GlaxoSmithKline Plc
Good T Cells Inc
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoGenyx LLC
Ichnos Sciences Inc
Idorsia Pharmaceutical Ltd
IL-2Rx Inc
Iltoo Pharma
Immplacate
Immune Modulation Inc
Immungenetics AG
ImmunoQure AG
Immunwork Inc
Immupharma Plc
InnoCare Pharma Ltd
Innovimmune Biotherapeutics Inc
iSD Immunotech ApS
Janus Biotherapeutics Inc
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Jura Bio Inc
K-Stemcell Co Ltd
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
Kezar Life Sciences Inc
Kine Sciences
Kiniksa Pharmaceuticals Ltd
Kyowa Kirin Co Ltd
Lead Discovery Center GmbH
MedAnnex Ltd
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
MorphoSys AG
Mount Tam Biotechnologies Inc
Nektar Therapeutics
Neovacs SA
Novartis AG
Octagon Therapeutics Inc
Omeros Corp
Pfizer Inc
Pharchoice Therapeutics Inc
ProNoxis AB
Provention Bio Inc
Ra Pharmaceuticals Inc
ReAlta Life Sciences Inc
RedHill Biopharma Ltd
Regen BioPharma Inc
RemeGen Ltd
Resolve Therapeutics LLC
Rheos Medicines Inc
Sanofi
Sareum Holdings Plc
SBI Biotech Co Ltd
Sengenics International Pte Ltd
Shanghai GeneChem Co Ltd
Shanghai Junshi Bioscience Co Ltd
SinoMab Bioscience Ltd
StingInn LLC
Suzhou Sinovent Pharmaceuticals Co Ltd
SynAct Pharma AB
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
TherapyX Inc
Tonix Pharmaceuticals Holding Corp
UCB SA
Viela Bio Inc
Visterra Inc
Voronoi
Xencor Inc
XTL Biopharmaceuticals Ltd
ZyVersa Therapeutics Inc